Edwards Lifesciences Acquires Embol-X

In a transaction that will add to the company's cardiac surgery portfolio, Edwards Lifesciences Corp. (Irvine, CA, USA) has acquired various assets of Embol-X, Inc. (Sacramento, CA, USA). Financial terms were not disclosed.

The acquisition includes all technology and intellectual property associated with Embol-X's surgically placed, intra-aortic embolic management system. In use, this expandable, wire-mesh filtration system is placed inside the aorta above the aortic clamp, where it can capture particles in the bloodstream that otherwise would remain in the patient's circulatory system during cardiac surgery. The technology is designed to capture emboli such as blood clots or tissue fragments. In a US clinical study, 97% of the Embol-X filters tested were found to have captured embolic material.

"We believe that the Embol-X system represents a new category of patient care, providing an enhanced measure of safety or embolic protection during open heart surgery,” noted Anita B. Bessler, corporate vice president of global franchise management for Edwards.





Related Links:
Edwards
Embol-X